Closing remarks

  • R. Guillemin
Part of the New Vistas in Drug Research book series (DRUG RESEARCH, volume 1)


As you all know I am not directly working in the field of the studies of this Symposium. The closest I ever came to that was after we had isolated somatostatin some years ago, synthesized it, made antibodies to it and distributed those antibodies to quite a few colleagues, when it was found that somatostatin was co-localized with the dopaminergic neurons in the basal nuclei and when, later on, the group at Albert Einstein reported that somatostatin appeared to be dramatically decreased in its concentration in the cortex of patients with Alzheimer’s, while other kinds of neuropeptides were not. So, I come here only as the neuroendocrinologist that I am and I am sure that you will have already thought yourselves about much of what I will say regarding this symposium.


Dopaminergic Neuron Small Peptide Early Marker Basal Nucleus Senile Dementia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag/Wien 1990

Authors and Affiliations

  • R. Guillemin
    • 1
  1. 1.The Whittier Institute for Diabetes and EndocrinologyLa JollaUSA

Personalised recommendations